IT1263831B - Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina - Google Patents

Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina

Info

Publication number
IT1263831B
IT1263831B ITMI930141A ITMI930141A IT1263831B IT 1263831 B IT1263831 B IT 1263831B IT MI930141 A ITMI930141 A IT MI930141A IT MI930141 A ITMI930141 A IT MI930141A IT 1263831 B IT1263831 B IT 1263831B
Authority
IT
Italy
Prior art keywords
acid
basic
cyclodextrine
constituted
inclusion complexes
Prior art date
Application number
ITMI930141A
Other languages
English (en)
Inventor
Paolo Chiesi
Paolo Ventura
Massimo Pasini
Maria Vikmon
Original Assignee
Paolo Chiesi
Paolo Ventura
Massimo Pasini
Maria Vikmon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paolo Chiesi, Paolo Ventura, Massimo Pasini, Maria Vikmon filed Critical Paolo Chiesi
Publication of ITMI930141A0 publication Critical patent/ITMI930141A0/it
Priority to ITMI930141A priority Critical patent/IT1263831B/it
Priority to DE69431747T priority patent/DE69431747D1/de
Priority to CZ951943A priority patent/CZ284606B6/cs
Priority to HU9502251A priority patent/HU218796B/hu
Priority to KR1019950702913A priority patent/KR960700074A/ko
Priority to EP94905707A priority patent/EP0681481B1/en
Priority to PCT/EP1994/000205 priority patent/WO1994016733A1/en
Priority to AU59710/94A priority patent/AU691115B2/en
Priority to CA002154874A priority patent/CA2154874A1/en
Priority to US08/481,519 priority patent/US5855916A/en
Priority to AT94905707T priority patent/ATE228013T1/de
Priority to BR9406779A priority patent/BR9406779A/pt
Priority to NZ261115A priority patent/NZ261115A/en
Priority to JP6516681A priority patent/JPH08508711A/ja
Priority to IL10846094A priority patent/IL108460A/en
Priority to ZA94572A priority patent/ZA94572B/xx
Publication of ITMI930141A1 publication Critical patent/ITMI930141A1/it
Priority to NO952981A priority patent/NO952981L/no
Priority to FI953590A priority patent/FI953590A/fi
Application granted granted Critical
Publication of IT1263831B publication Critical patent/IT1263831B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Si descrivono complessi di inclusione a tre componenti costituiti da un farmaco di tipo basico, una ciclodestrina e un acido, caratterizzati da una elevatissima solubilità acquosa sia della molecola ospite che della ciclodestrina.
ITMI930141A 1993-01-29 1993-01-29 Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina IT1263831B (it)

Priority Applications (18)

Application Number Priority Date Filing Date Title
ITMI930141A IT1263831B (it) 1993-01-29 1993-01-29 Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
CA002154874A CA2154874A1 (en) 1993-01-29 1994-01-26 Highly soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin
AT94905707T ATE228013T1 (de) 1993-01-29 1994-01-26 Hochlösliche multikomponenten-inklusionskomplexe, welche ein basisches arzneimittel, eine säure und ein zyklodextrin enthalten
HU9502251A HU218796B (hu) 1993-01-29 1994-01-26 Többkomponensű, bázikus gyógyszerhatóanyagot, savat és ciklodextrint tartalmazó zárványkomplexek
KR1019950702913A KR960700074A (ko) 1993-01-29 1994-01-26 고용해성다성분봉입체착화합물(Highy soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin)
EP94905707A EP0681481B1 (en) 1993-01-29 1994-01-26 Highly soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin
PCT/EP1994/000205 WO1994016733A1 (en) 1993-01-29 1994-01-26 Highly soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin
AU59710/94A AU691115B2 (en) 1993-01-29 1994-01-26 Highly soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin
DE69431747T DE69431747D1 (de) 1993-01-29 1994-01-26 Hochlösliche multikomponenten-inklusionskomplexe, welche ein basisches arzneimittel, eine säure und ein zyklodextrin enthalten
US08/481,519 US5855916A (en) 1993-01-29 1994-01-26 Highly soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin
CZ951943A CZ284606B6 (cs) 1993-01-29 1994-01-26 Vícesložkové inklusní komplexy a způsob jejich výroby
BR9406779A BR9406779A (pt) 1993-01-29 1994-01-26 Complexos de inclusão de multicomponentes altamente solúveis contendo uma droga de tipo básico um ácido e uma ciclodextrina
NZ261115A NZ261115A (en) 1993-01-29 1994-01-26 Cyclodextrin complexes comprising basic drug and an acid
JP6516681A JPH08508711A (ja) 1993-01-29 1994-01-26 塩基型薬剤と酸とシクロデキストリンを含有する高可溶性多成分包接錯体
IL10846094A IL108460A (en) 1993-01-29 1994-01-27 Multi-component inclusion compounds that are easily soluble and contain a base, acid and cyclodextrin type drug
ZA94572A ZA94572B (en) 1993-01-29 1994-01-27 Highly soluble multicomponent inclusion complexes containing a base type drug an acid and a cyclodextrin
NO952981A NO952981L (no) 1993-01-29 1995-07-27 Höyopplöselige flerkomponent-innleiringskomplekser inneholdende et basisk medikament, en syre og et cyklodekstrin
FI953590A FI953590A (fi) 1993-01-29 1995-07-27 Erittäin liukoiset monta komponenttia sisältävät sulkeumakompleksit, jotka sisältävät emästyyppistä lääkeainetta, happoa sekä syklodekstriiniä

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI930141A IT1263831B (it) 1993-01-29 1993-01-29 Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina

Publications (3)

Publication Number Publication Date
ITMI930141A0 ITMI930141A0 (it) 1993-01-29
ITMI930141A1 ITMI930141A1 (it) 1994-07-30
IT1263831B true IT1263831B (it) 1996-09-04

Family

ID=11364792

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI930141A IT1263831B (it) 1993-01-29 1993-01-29 Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina

Country Status (18)

Country Link
US (1) US5855916A (it)
EP (1) EP0681481B1 (it)
JP (1) JPH08508711A (it)
KR (1) KR960700074A (it)
AT (1) ATE228013T1 (it)
AU (1) AU691115B2 (it)
BR (1) BR9406779A (it)
CA (1) CA2154874A1 (it)
CZ (1) CZ284606B6 (it)
DE (1) DE69431747D1 (it)
FI (1) FI953590A (it)
HU (1) HU218796B (it)
IL (1) IL108460A (it)
IT (1) IT1263831B (it)
NO (1) NO952981L (it)
NZ (1) NZ261115A (it)
WO (1) WO1994016733A1 (it)
ZA (1) ZA94572B (it)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
AUPM456894A0 (en) * 1994-03-18 1994-04-14 Glyzinc Pharmaceuticals Limited Treatment for gastric disorders
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
CA2259418A1 (en) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
EP0893121B1 (en) * 1997-06-27 2002-03-13 Akzo Nobel N.V. Oral liquid medicine solution
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
JP2000080123A (ja) * 1998-09-03 2000-03-21 Toagosei Co Ltd シアノアクリレート用硬化促進剤
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
FI982733A (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
FI109332B (fi) * 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
US6740639B1 (en) * 2000-03-29 2004-05-25 Council Of Scientific & Industrial Research Inclusion complees of a high potent opioid peptide, pharmaceutical compositions and method of treatment
GB0015239D0 (en) * 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
US6663897B2 (en) 2001-02-06 2003-12-16 Dsm Ip Assets B.V. Oral itraconazole formulations and methods of making the same
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
WO2003052117A2 (en) * 2001-09-19 2003-06-26 Massachusetts Institute Of Technology Methods and products related to non-viral transfection
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
EP1494998A2 (en) 2002-03-01 2005-01-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
JP2005535602A (ja) * 2002-05-31 2005-11-24 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 新規コナゾール結晶形及び関連方法、医薬組成物及び方法
CN100360117C (zh) 2002-06-21 2008-01-09 转化医药公司 具有提高的溶出度的药物组合物
SI1542668T1 (sl) * 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazol sestavljena formulacija in postopek
US7648678B2 (en) 2002-12-20 2010-01-19 Dako Denmark A/S Method and system for pretreatment of tissue slides
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
CN1515260B (zh) * 2003-06-26 2010-05-05 沈阳药科大学 含hpcd的桂利嗪粉针剂和其固体制剂及其制备方法
JP5216216B2 (ja) 2003-11-13 2013-06-19 ハンミ サイエンス カンパニー リミテッド 免疫グロブリンＦｃ領域をキャリアとして含む薬剤学的組成物
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1570862A1 (en) * 2004-02-25 2005-09-07 JPM - The Jordanian Pharmaceutical Manufacturing Co. Ltd. Highly soluble binary cyclodextrin inclusion complexes
JP2007525502A (ja) * 2004-02-26 2007-09-06 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド コナゾール類の新規な結晶形態並びにそれらの製造および使用方法
KR100663079B1 (ko) * 2004-06-24 2007-01-02 주식회사 씨티씨바이오 이트라코나졸 함유 고체분산체의 제조방법
WO2006052921A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Cyclodextrin solubilizers for liquid and semi-solid formulations
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
WO2007047253A2 (en) * 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
CN101314045B (zh) * 2008-05-09 2013-01-23 沈阳药科大学 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
PT2306971E (pt) 2008-07-03 2015-06-18 Univ Virginia Patent Found Dosagem unitária de apadenoson
PL2331092T3 (pl) 2008-08-21 2014-08-29 Univ Johns Hopkins Sposoby i kompozycje do podawania 3-halopirogronianiu i związków pochodnych w leczeniu nowotworu
AU2010253905B2 (en) 2009-05-29 2014-10-02 Cydex Pharmaceuticals, Inc. Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
JP5803150B2 (ja) * 2011-03-02 2015-11-04 三菱瓦斯化学株式会社 ピロロキノリンキノンーシクロデキストリン包接体
CN105744944B (zh) 2013-09-09 2020-07-07 卡尼姆盖德治疗学公司 免疫系统调节器
AU2015206629B2 (en) * 2014-01-14 2020-03-05 The Johns Hopkins University Cyclodextrin compositions encapsulating a selective ATP inhibitor and uses thereof
US9896614B2 (en) 2014-11-05 2018-02-20 Halliburton Energy Services, Inc. Delayed acid breaker systems for filtercakes
WO2016144650A1 (en) 2015-03-06 2016-09-15 Canimguide Therapeutics Ab Immune system modulators and compositions
CN106539752B (zh) * 2015-09-18 2019-10-29 成都康弘药业集团股份有限公司 一种含有阿立哌唑的口服溶液及其制备方法
US10751306B2 (en) 2015-11-06 2020-08-25 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
EP4149427A1 (en) 2020-06-11 2023-03-22 Sentiss Pharma Private Limited Ophthalmic compositions comprising a combination of fluoroquinolone antibacterial agent and an anti-inflammatory agent
KR102356618B1 (ko) * 2021-11-17 2022-02-08 명지대학교 산학협력단 신규 포접복합체 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS60185772A (ja) * 1984-03-05 1985-09-21 Mitsui Pharmaceut Inc 安定なカルモフ−ル−β−シクロデキストリンの包接化合物
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
JP2571199B2 (ja) * 1987-11-25 1997-01-16 塩水港精糖株式会社 溶解性の高いサイクロデキストリンの製造方法
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids

Also Published As

Publication number Publication date
HU218796B (hu) 2000-12-28
IL108460A0 (en) 1994-04-12
EP0681481B1 (en) 2002-11-20
ITMI930141A0 (it) 1993-01-29
HUT72500A (en) 1996-05-28
AU5971094A (en) 1994-08-15
IL108460A (en) 1999-01-26
CZ194395A3 (en) 1996-01-17
BR9406779A (pt) 1996-02-06
EP0681481A1 (en) 1995-11-15
DE69431747D1 (de) 2003-01-02
AU691115B2 (en) 1998-05-07
ATE228013T1 (de) 2002-12-15
NZ261115A (en) 1996-11-26
NO952981D0 (no) 1995-07-27
JPH08508711A (ja) 1996-09-17
WO1994016733A1 (en) 1994-08-04
CZ284606B6 (cs) 1999-01-13
US5855916A (en) 1999-01-05
HU9502251D0 (en) 1995-09-28
FI953590A0 (fi) 1995-07-27
ZA94572B (en) 1994-09-13
KR960700074A (ko) 1996-01-19
CA2154874A1 (en) 1994-08-04
FI953590A (fi) 1995-09-14
NO952981L (no) 1995-07-27
ITMI930141A1 (it) 1994-07-30

Similar Documents

Publication Publication Date Title
IT1263831B (it) Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
CA2119154A1 (en) Derivatives of Cyclodextrins Exhibiting Enhanced Aqueous Solubility and the Use Thereof
CA2074186A1 (en) Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
ATE196426T1 (de) Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate
ITMI940790A0 (it) Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido una ciclodestrina e una base
CA2289202A1 (en) Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent
ATE219109T1 (de) Acylierte cyclodextrinderivate
IT1319767B1 (it) Procedimento per trivellare una formazione sotterranea mediantel'utilizzo di una punta da perforazione oscillante.
DK1161452T3 (da) Kovalent forbundne insulindimerer
BR0001569A (pt) Inibidores da uroquinase do tipo 2-piridinilguanidina
NO20032788L (no) Modafinil-forbindelse og cyklodekstrinblandinger
NO890567D0 (no) Anthracyklin-derivater.
DE69434356D1 (de) Inclusion-Komplex von Beta-Cyclodextrin mit Diclofenac
BR9105822A (pt) Clatratos de peroxiacidos
DE58907942D1 (de) Lacke enthaltend Molybdändisulfid.
DE69707927D1 (de) Verbesserungen bezüglich langwirksamer antibiotika
FI102462B1 (fi) Menetelmä nimesulidin syklodekstriinikompleksin valmistamiseksi
FI925869A (fi) Foerfarande foer infoerande av en peptid i cytosol
FR2623807B1 (fr) Clathrates formes par une cyclodextrine et des derives de la cyano-5 prostacycline, et medicaments qui en contiennent
FI941149A (fi) 2,4-diamino-3-hydroksikarboksyylihapon johdannaisia
DE69212267D1 (de) Echinocandin-B-Derivat
NO920050L (no) Trifluormetyl-1-karba(1-detia)cefemer
DE69627184D1 (de) 3-aminoethyl-n-amidino-2,5-dihydropyrrol derivative mit arginine-mimetischen eigenschaften
ES2076642T3 (es) Procedimiento para la mono-orto-hidroxialquilacion selectiva de derivados de piridina sustituidos en posicion 4.
FI904932A (fi) Optiskt aktiva tiazetokinolin-3 -karboxylsyraderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska kompositioner.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960130